Lixte Biotechnology Statistics
Share Statistics
Lixte Biotechnology has 2.25M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 2.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.80M |
| Failed to Deliver (FTD) Shares | 18.82K |
| FTD / Avg. Volume | 3.26% |
Short Selling Information
The latest short interest is 447.99K, so 19.92% of the outstanding shares have been sold short.
| Short Interest | 447.99K |
| Short % of Shares Out | 19.92% |
| Short % of Float | 24.94% |
| Short Ratio (days to cover) | 0.31 |
Valuation Ratios
The PE ratio is -0.88 and the forward PE ratio is null.
| PE Ratio | -0.88 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.12 |
| P/FCF Ratio | -1.05 |
| PEG Ratio | n/a |
Enterprise Valuation
Lixte Biotechnology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 13.73, with a Debt / Equity ratio of 0.
| Current Ratio | 13.73 |
| Quick Ratio | 13.73 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.27% and return on capital (ROIC) is -127.42%.
| Return on Equity (ROE) | -1.27% |
| Return on Assets (ROA) | -1.18% |
| Return on Capital (ROIC) | -127.42% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.70M |
| Employee Count | 3 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.69% in the last 52 weeks. The beta is -0.17, so Lixte Biotechnology 's price volatility has been lower than the market average.
| Beta | -0.17 |
| 52-Week Price Change | -5.69% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 2.29 |
| Relative Strength Index (RSI) | 50.92 |
| Average Volume (20 Days) | 576.54K |
Income Statement
In the last 12 months, Lixte Biotechnology had revenue of $0 and earned -$5.09M in profits. Earnings per share was $-2.66.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -5.09M |
| Net Income | -5.09M |
| EBITDA | 3.21K |
| EBIT | - |
| Earnings Per Share (EPS) | -2.66 |
Balance Sheet
The company has $4.20M in cash and $0 in debt, giving a net cash position of $4.20M.
| Cash & Cash Equivalents | 4.20M |
| Total Debt | 0 |
| Net Cash | 4.20M |
| Retained Earnings | -48.48M |
| Total Assets | 1.70M |
| Working Capital | 1.36M |
Cash Flow
In the last 12 months, operating cash flow was -$4.29M and capital expenditures $0, giving a free cash flow of -$4.29M.
| Operating Cash Flow | -4.29M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.29M |
| FCF Per Share | -2.25 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
LIXT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -133.67% |
| FCF Yield | -96.15% |
Analyst Forecast
Currently there are no analyst rating for LIXT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 5, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -41.45 |
| Piotroski F-Score | 1 |